ONC - Tracking Baker Brothers Portfolio - Q1 2025 Update
2025-06-17 21:14:09 ET
This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 05/15/2025. The 13F portfolio value decreased from $9.36B to $9.04B. Although there are ~100 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. There are 26 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. The largest five stakes are BeiGene, Incyte, ACADIA Pharma, Madrigal Pharma, and Insmed. They add up to ~67% of the portfolio. Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update for the fund's moves during Q4 2024....
Tracking Baker Brothers Portfolio - Q1 2025 Update